Photobiomodulation Equipment and Training - THOR Photomedicine

Select Region

Information contained on this page may not be appropriate for your region, please select your region from below. To navigate back to this region selector, please click "Region" in the footer.
Do More With A THOR
Lots of happy THOR customer testimonials
NovoTHOR Whole Body Light Pod

French Version

Photobiomodulation (PBM) reduces severity and duration of oral mucositis, and can be used for prevention.

The effect of Photobiomodulation (PBM Therapy) previously known as Low Level Laser Therapy (LLLT) on oral mucositis (by laser or LED) has been reported in 47 randomised controlled clinical trials. These includes patients undergoing chemotherapy, radiotherapy or haematopoietic stem cell transplantation (HSCT) in both pediatric and and adult populations. Most of the studies are therapeutic (treating symptoms) but some clinical trials have shown that treatment concurrent with cancer therapies can be preventative.


  • Oral mucositis
  • Hyposalivation and xerostomia
  • Lymphoedema


  • Radiation dermatitis
  • Dysphagia
  • Trismus
  • Fibrosis
  • Pain control


"Our results have indicated that the use of low power laser in HSCT patients is a powerful instrument in the treatment of overt OM and is now a standard procedure in this group of patients in our hospital."

Clinical Trial authors Antunes HS, Ferreira EM, de Matos VD, Pinheiro CT, Ferreira CG

"The ease of use of PBM, high patient acceptance, and the positive results achieved, make this therapy feasible for the prevention and treatment of OM in young patients."

Clinical Trial authors Abramoff MM, Lopes NN, Lopes LA, Dib LL, Guilherme A, Caran EM, Barreto AD, Lee ML, Petrilli AS

"There is consistent evidence from small high-quality studies that red and infrared PBM can partly prevent development of cancer therapy-induced OM. PBM also significantly reduced pain, severity and duration of symptoms in patients with cancer therapy-induced OM."

Clinical Trial authors Bjordal JM, Bensadoun RJ, Tuner J, Frigo L, Gjerde K, Lopes-Martins RA

"Our results indicate that the use of upfront low power laser in patients who have undergone HSCT is a powerful instrument in reducing the incidence of OM and is now standard in our center."

Clinical Trial authors Antunes HS, de Azevedo AM, da Silva Bouzas LF, Adao CA, Pinheiro CT, Mayhe R, Pinheiro LH, Azevedo R, D'Aiuto de Matos V, Rodrigues PC, Small IA, Zangaro RA, Ferreira CG

"Laser therapy was effective in preventing and treating oral effects induced by radiotherapy and chemotherapy, thus improving the patient's quality of life."

Clinical Trial authors Zanin T, Zanin F, Carvalhosa AA, de Souza Castro PH, Pacheco MT, Zanin IC, Junior AB

Are you a patient? Pass these documents on to your Oncologist

What is PBM ?

Photobiomodulation (PBM) therapy, (previously known as Low Level Laser Therapy or LLLT) is the application of light to tissues to reduce inflammation and improve healing. It works by increasing cellular energy (ATP) and reducing free radicals (oxidative stress). There are over 700 randomised controlled clinical trials published on PBM for a wide range of painful and non healing applications including 47 controlled clinical trials on oral mucositis.

How PBM works

One of the main effects of PBM is on mitochondrial function: There are hundreds of different cell types in the body, each performing different functions, they all contain lots of mitochondria, (cellular power plants) which generate most of the cell's supply of energy (ATP). Mitochondria are also involved in a range of other cellular processes, including signalling, stem cell differentiation, inflammation, cell survival, apoptosis and are consequently implicated in many diseases.

Mitochondria in stressed or ischaemic tissues produce too much mitochondrial nitric oxide (mtNO) which binds to cytochrome c oxidase, competitively displacing oxygen and consequently reducing ATP, but this inhibition of mitochondrial respiration significantly increases production of ROS (free radicals). These excess ROS trigger the process of inflammation, cell death and subsequently oral mucositis.

Light of the correct wavelength (generated by low intensity lasers and LED's), when applied to stressed tissues, is absorbed by cytochrome c oxidase. The light displaces the mtNO thereby reducing oxidative stress and increasing ATP production; this reduces inflammation and increases cell metabolism.

The subsequent cascade of downstream metabolic effects have been shown to include changes in gene transcription (NF-kB and AP-1), activation of latent TGF-β1, increased exchange of Ca2+, secretion of growth factors, activation of enzymes & many secondary messengers.

Within hours (and sometimes minutes) following PBM, increases in cellular activity have been shown in vitro and in vivo in neutrophils, macrophages, fibroblasts, mast cells, endothelial cells and keratinocytes. Reduced inflammatory markers including prostaglandin E2, interleukin 1ß and TNFα have also been seen in many studies.

Clinical trials show a significant improvement in healing of wounds and reduction of pain. A recent systematic review on PBM for OM found that it reduces pain, severity and duration of chemotherapy and radiotherapy induced oral mucositis.

The Multinational Association of Supportive Care in Cancer (MASCC) now recommend PBM for the prevention of oral mucositis in adult patients receiving hematopoietic stem cell transplantation conditioned with high-dose chemotherapy. A new suggestion was made for low-level laser for the prevention of oral mucositis in patients undergoing radiotherapy, without concomitant chemotherapy, for head and neck cancer.
Source: www.mascc.org/mucositis-guidelines

Prices from US$16,000 to US$40,000 (£12,495–£31,995 + VAT)

THOR LX2 Dental Package for a range of oral pathologies, orthodontic procedures and orofacial pain syndromes.

CLICK HERE to contact sales Training course information

Photobiomodulation (PBM) / Low Level Laser Therapy (LLLT) oral mucositis Photobiomodulation (PBM) / Low Level Laser Therapy (LLLT) oral mucositis Photobiomodulation (PBM) / Low Level Laser Therapy (LLLT) oral mucositis Photobiomodulation (PBM) / Low Level Laser Therapy (LLLT) oral mucositis Photobiomodulation (PBM) / Low Level Laser Therapy (LLLT) oral mucositis Photobiomodulation (PBM) / Low Level Laser Therapy (LLLT) oral mucositis

Annette Quinn - Oral Mucositis Academy of Laser Dentistry 2016 View it on YouTube

Product information and purchase enquiry

Sorry for the long form.

We are a global company and our computer needs to know who to direct your enquiry to.

* Mandatory field - this automatically directs your enquiry to the correct department

THOR Photobiomodulation Newsletter

See previous edition. Please add me to the monthly THOR training, research and conference Newsletter.

Our customers include: Harvard Medical School, Massachusetts General Hospital, British Army, RAF, Royal Navy, Team GB, Manchester United, MIT, Harvard School of Public Health, Cedars Sinai, City of Hope, USUHS
THOR Customers

THOR Photomedicine Ltd is an ISO 13485:2016 certified medical device company.

The THOR LX2.3 Photobiomodulation system has a medical CE mark (EC certificate). It is indicated for oral mucositis, tendinopathies, joint pain, neck pain and back pain for marketing in the UK, EU and Australia.

The THOR LX2.3 Photobiomodulation system is also FDA Cleared for marketing in the United States for: Temporary increase in local blood circulation, temporary relief of minor muscle and joint aches, pains and stiffness and relaxation of muscles; for muscle spasms, and minor pain and stiffness associated with arthritis.

Excluding the THOR LED Helmet, THOR LX2 and NovoTHOR systems are manufactured under conditions fulfilling the quality system requirements of Annex II, excluding (4), of the directive 93/42/EEC as amended and satisfy the applicable international harmonised standards.

Positive systematic reviews published by:

The British Medical Journal (BMJ), The Lancet, the International Association for the Study of Pain (IASP), the World Health Organisation (WHO), the Multinational Association for Supportive Care in Cancer (MASCC), the European Society for Medical Oncology (ESMO)

Appropriate regulatory clearance or approvals include:

Quality certificates